GPT and fatty liver disease: Reduction in BMI, cholesterol, GGT, ballooning, and fibrosis. Improvement in liver steatosis and serum ALT level (125).Lowered hepatic lactosylceramides (LCER 16:0, 18:0). Mice received oral empagliflozin for 12 weeks 10 mg/kg/day) (145)